Olympia Pharmacy (OPS International, Inc.), Orlando, FL

Is Olympia Pharmacy (OPS International, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.

Does Olympia Pharmacy (OPS International, Inc.) hold a Florida pharmacy license?

The Florida Board of Pharmacy lists 6 licenses for this name and city, as of Nov 15, 2026: PH27363 for OPS INTERNATIONAL INCORPORATED (dba OLYMPIA PHARMACEUTICALS), ORLANDO, status Clear, PH27414 for OPS INTERNATIONAL INCORPORATED (dba OLYMPIA PHARMACEUTICALS), ORLANDO, status Clear, PH32627 for OPS INTERNATIONAL INCORPORATED (dba OLYMPIA PHARMACY), ORLANDO, status Clear and PH32707 for OPS INTERNATIONAL INC. (dba OLYMPIA PHARMACY), ORLANDO, status Clear, and 2 more listed below. The Texas State Board of Pharmacy also lists nonresident license 33825 for OLYMPIA PHARMACY, ORLANDO, FL, status Active, as of Nov 15, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 7422 for OPS International Inc, Orlando, FL, status Active and license OSP 5968 for OPS International Incorporated, Orlando, FL, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054023245 for OPS INTERNATIONAL INC, ORLANDO, FL, status ACTIVE, license 054018748 for OPS INTERNATIONAL INC, ORLANDO, FL, status CLOSED and license 054021641 for OPS INTERNATIONAL INC, ORLANDO, FL, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003802 for OPS INTERNATIONAL INC. DBA OLYMPIA PHARMACY (dba OLYMPIA PHARMACY), ORLANDO, FL, status ACTIVE (CURRENT) and license PCN.0002712 for OPS INTERNATIONAL INC. (dba OLYMPIA PHARMACEUTICALS), ORLANDO, FL, status INACTIVE, as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0013119 for OPS International Incorporated, ORLANDO, FL, status Active, license AD-0010094 for OPS INTERNATIONAL INCORPORATED, ORLANDO, FL, status Active, license A9-0001820 for OPS International Inc. (dba Olympia Pharmacy), ORLANDO, FL, status Closed and license A9-0012540 for OPS International Incorporated, ORLANDO, FL, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301009877 for OPS International Incorporated, Orlando, FL, status Active and license 5301012402 for OPS INTERNATIONAL INCORPORATED, ORLANDO, FL, status Active, as of Nov 10, 2026.

Has Olympia Pharmacy (OPS International, Inc.) had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 4 Form 483s (latest Sep 3, 2026) for Olympia Pharmacy (OPS International, Inc.). State board actions: no Florida Board of Pharmacy action on licenses PH27363, PH27414, PH32627 and PH32707 and the others below or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists 2 actions: “Through a disciplinary action of the Board, the license is publicly reproved subject to terms and conditions in the decision” dated May 23, 2024, case AC 7088 on nonresident license NRP 1525 and “Through a disciplinary action of the Board, the license is publicly reproved subject to terms and conditions in the decision” dated May 23, 2024, case AC 7088 on nonresident license NSC 100818.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
OPS International, Inc.; Olympia Pharmacy
Location
Orlando, FL
Type as FDA labels it
503B
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
4
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 3, 2026
FDA Data Dashboard inspections
5 inspections: 3 OAI, 2 VAI; 6 published Form 483s
Form 483 text on this page
5 Form 483s, 41 observations
State board records
License found: PH27363, Clear; PH27414, Clear; PH32627, Clear; PH32707, Clear; PH24080, Closed; PH27446, Closed

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as OPS International, Inc., (dba Olympia Pharmacy), a 503B facility, with 5 dated actions.

Document
Sep 3, 2026Form 483483 Issued 09/03/2026fda.gov
Aug 8, 2025Amended Form 483Amended 483 Issued 08/08/2025fda.gov
May 29, 2024Form 483483 Issued 05/29/2024FDA copy (archived)
Feb 22, 2023Regulatory meetingRegulatory Meeting Held 02/22/2023Not linked by FDA
Mar 2, 2022Form 483483 Issued 03/02/2022fda.gov

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists OPS International Inc, Orlando, FL (FEI number 3009724085), matched to this page by exact name, city and state. It lists 5 inspections: 3 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 8, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30097240851279691
May 29, 2024Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30097240851237161
Apr 13, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30097240851048185
Dec 4, 2014Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3009724085907206
Mar 21, 2013Official Action Indicated (OAI)Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI)3009724085825265

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 41 numbered observations in all, across 5 inspections ending Apr 13, 2018 to Sep 3, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 20, 2026 to Sep 3, 2026: 8 observations

Firm on the cover
OPS International Inc dba Olympia Pharmaceuticals, 6700 Conroy Rd Ste 155, Orlando, FL 32835-3515
FEI number
3009724085
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from 503B list, actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

(A) The firm's environmental monitoring procedure does not require viable environmental monitoring during the initial aseptic setup of the <Redacted B4> filling line within the <Redacted B4> or during the initial aseptic setup of the <Redacted B4> automated filling machine positioned under <Redacted B4> HEPA-filtered unidirectional airflow enclosure. Per SOP-009, Environmental Monitoring of the Controlled Production Areas, environmental monitoring is not required to commence until aseptic connections setup activities have occurred.

(1) On August 26, 2026, we observed operator <Redacted B4> performing set-up of the <Redacted B4> for the <Redacted B4> automated filling machine (Equipment ID # <Redacted B4> for the filling of Calcium Chloride (Lot #H24A01-26). No environmental monitoring plates were present within the ISO 5 critical area under the <Redacted B4> unidirectional airflow unit during this setup activity.

(2) According to the batch record for Myer's Cocktail (Lot# G27A0S-26, Exp. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.

Specifically,

{A) Your firm has not adequately demonstrated that <Redacted B4> sterilized machine <Redacted B4> parts and accessories used in aseptic filling maintain their sterile state during the established <Redacted B4> post-sterilization hold time in a controlled, non-classified area. The supporting microbiological evaluation consisted of swabbing part surfaces and incubating samples in <Redacted B4> medium <Redacted B4> for <Redacted B4>

(1) Your firm has not provided adequate scientific justification that these incubation conditions are suitable for recovering and detecting microorganisms that may be encountered ifthe sterile barrier is compromised during storage within the non-classified area.

{2) The provided recorded associated with the sampling, in-house incubation, and results of the swab samples lacked the following critical information:

111 Ill Ill

Actual incubation temperature Date and time samples were placed in the incubator Date and time samples were removed from the incubator

Ill

Identity of the person who read the results ...

Read the full 483 (PDF on fda.gov)

Observation 3

Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time of performance.

Specifically,

(B) Batch record review of Myer's Cocktail (Lot# G27A0S-26, Exp. 26 Nov 2026) revealed that equipment set-up of the <Redacted B4> filling line, located inside the ISO-5 in Suite <Redacted B4> began on 30 July 2026 at 08:01 and was completed by Sterile Tech <Redacted B4> at 08:06 on 30 July 2026 -a total elapsed time of five minutes. However, set-up encompassed installation of <Redacted B4> chambers: <Redacted B4> where each require multiple set up steps. -For example, the <Redacted B4> chamber alone required the installation of multiple components, including the <Redacted B4>, and other associated parts.

(C) Visual inspectors did not perform vial <Redacted B4> as required by Section 9.3 of SOP-007, Visual Inspection of Sterile Drug Products, and inspection steps performed in practice differed from those written in the procedure.

(1) On August 20, 2026, Sterile Tech <Redacted B4> as observed conducting visual inspection of Amino Blend (Lot# H11A03-26) and failed to perform v ial <Redacted B4>. 1. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, the w visual inspection qualification <Redacted B4> used to qualify personnel performing 100% visual inspection of injectable drug products are not adequately characterized or designed to challenge inspectors' ability to detect particulates at or near the threshold of visual detectability. For example:

(A) Your firm has not established the size or size range of the particulate defects contained in the qualification units intended to challenge visual inspectors to detect the smallest contaminants possible for an inspector with 20/20 vision. Although <Redacted B4> defect vials containing particulates were submitted for size characterization, the analysis was performed using the particle-size distribution method described in USP <429>, as documented in the Certificates of Analysis. The resulting data do not establish the size of the individual particulate defect contained in each qualification unit. ...

Read the full 483 (PDF on fda.gov)

Observation 5

The written stability program for drug products does not include reliable, meaningful and specific test methods.

Specifically, your firm assigns a <Redacted B4> beyond-use date (BUD) to Sermorelin Acetate 0.9 mg/ml Injection based on your contract laboratory stability study. However, your firm failed to provide adequate demonstration that the analytical procedure can detect relevant degradation-related changes. Your method validation report for Sermorelin Acetate, approved on August 22, 2025, does not include a mass balance assessment to demonstrate that the analytical method can adequately account for the drug substance and its degradation products, supporting the method's stability-indicating capability and reliability.

Observation 6

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.

(A) Your firm utilizes <Redacted B4> QA-access-controlled cabinets for the storage of sterilized machine 6 parts <Redacted B4> and accessories. <Redacted B4>. During inspection of these cabinets <Redacted B4> components, including a stopper bowl that directly contacts product stoppers, were observed without sterilization-status labels. The components lacked information identifying the applicable <Redacted B4> and sterilization date needed for personnel to determine whether the established sterile hold time had been exceeded.

Specifically,

(B) Sterilization-status labels are generated by operators; however, the firm did not demonstrate a system for reconciling generated labels to the individual equipment parts associated with each sterilization cycle.

Observation 7

Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

Specifically,

(A) SOP-035, Procurement, Receipt, and Inspection of Incoming Components and Materials, does not include a sampling plan specifying the number of containers to be sampled per shipment. According to the Senior Supply Chain Manager, <Redacted B4> sent from your <Redacted B4> warehouse to your facility for sampling. Additionally, no documentation exists for the sampling performed.

(B) Your firm failed to perform a specific identity test that includes a methanol limit test on each container of each lot of ethyl alcohol used as a pharmaceutical ingredient. On May 12, 2025, your firm received <Redacted B4> bottles of <Redacted B4> Ethyl Alcohol <Redacted B4> Proof (Batch # <Redacted B4> sampled, and methanol limit testing was not performed. This lot was used in the production of T-105 Injection (Papaverine Hydrochloride 30 mg/ml; Phentolamine Mesylate 1 mg/ml; Alprostadil 0.01 mg/ml), Lot #G08A10-26, BUD 04 JUL 2027. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Each component is not added to the batch by one person and verified by a second person ..

Specifically, a review of the batch record for Myer's Cocktail (Lot <Redacted B4>, Exp <Redacted B4> ) revealed that ingredients were added between <Redacted B4> on July 29, 2026, with no documented contemporaneous verification recorded after each individual addition. Instead, a single verification timestamp otro} ( <Redacted B4> was documented for this manufacturing step, more than two hours after the last ingredient was added.

verification recorded after each individual addition. Instead, a single verification timestamp otro} (,:l}was documented for this manufacturing step, more than two hours after the last ingredient was added.

Inspection Jul 28, 2025 to Aug 8, 2025: 3 observations

Firm on the cover
Olympia Pharmaceuticals, 6700 Conroy Rd Ste 155, Orlando, FL 32835-3515
FEI number
3009724085
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Specifically,

A. During the observation of air visualization study SO# FL-OYPP232701P-1 for your dynamic aseptic filling operation in Buffer Room <Redacted B4, Unit ID: <Redacted B4> the following deficiencies were noted:

1. The setup of vials, stoppers, and caps at the edge of the hood results in air arching and dragging, which prevents these critical components from receiving first air.

2. The filler needle isKo) (4) Ioriented within a <Redacted B4> laminar flow hood blocking unidirectional airflow.

3. The viable air monitor's functionality was not demonstrated during operation, therefore, there is no evidence to show that its placement could affect airflow in the critical area.

B. Dynamic FPC50 air visualization study:

1. Air visualization studies show air arching over stoppers, caps, and seals, indicating that these critical components are not receiving first air.

2. The filler needle is <Redacted B4> oriented within a <Redacted B4> laminar flow hood blocking unidirectional airflow.

3. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically,

A. Your firm lacks assurance that the light conditions are adequate for the visual inspection of amber-colored vials. Specifically:

1. Your procedure, SOP-007 "Visual Inspection ofSterile Drng Products" (version 13, effective 07/03/2025), requi1ts li~t intensity to be measured and documented [(o ) (~.LJ use, with a specified range o (6ff4 to 6>14 Lux. This range is not justified as bemg adequate for the effective inspection of amber vials.

2. Fmthe1more, while your fnm claims t~at li~t levels at the working height are consistently within an acceptable range of(b) (4 to (o) (4) Lux, your cmTent procedures and documentation do not require or demonstrate the measurement of light intensity at the actual working height of the inspection station. The light measurements are perfo1med at a fixed reference point on the table surface, which does not provide assurance that the illumination

AMENDMENT 1 ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the to produce aseptic conditions.

Specifically,

A. During the <Redacted B4> cleaning and disinfection of the ISO 5 Laminar Airflow Workstations (LAFWs) and Auto Filler Systems (AF) in Cleanroom 305 on 8/5/2025, I observed three cleaning operators exhibiting poor cleaning practices. Specifically, after the interior surfaces of the LAFWs (LAFW <Redacted B4> LAFW <Redacted B4>) ( <Redacted B4> and LAFW <Redacted B4>) ( <Redacted B4>) had been disinfected, I observed the cleaning operators stepping inside the LAFWs area and making contact with the cleaned interior walls of the LAFWs by leaning against them with their garments (backs, shoulders, or arms) while cleaning the auto-filler units.

B. Additionally, when the operator was cleaning the exterior walls of the LAFW <Redacted B4> I observed the operator's gloved hand contact the previously disinfected LAFW <Redacted B4> interior wall. This contact occurred when the operator used the side wall of the LAFW for support while reaching to clean the upper lateral exterior wall.

C. ...

Read the full 483 (PDF on fda.gov)

Inspection May 14, 2024 to May 29, 2024: 7 observations

Firm on the cover
Olympia Compounding Pharmacy, Outsourcing Facility
FEI number
3009724085
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Drug products failing to meet established specifications are not rejected.

Specifically, your firm released and distributed drn eroduct MICC (methionine 25mg, inositol 50mg, choline 50mg, cyanocobalamin 330 mcg) Lot# <Redacted B4>, BUD: 08 JUL 23 that failed finished product testing for low cyanocobalamin assay at 87.4%. On 03/24/2023 Lot# <Redacted B4> was rejected and dispositioned to be destroyed by your quality unit but your firm akeady began distributing this lot 10 days prior on 03/14/2023. A total of <Redacted B4> vials of lot<Redacted B4> were distributed from 03/14/2023 through 05/08/2023.

***This is a repeated observation from the previous FDA Inspection dated 2/14-2/23/22.

Observation 2

Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically,

1. Your firm failed to conduct a Performance Qualification (PQ) where your fir m establishe s all filling parameters including but not limited to cap placement involving circular vibrator speed and the cap crimping station involving crimp time and adequate in-process sampling for all your drug products produced on the <Redacted B4> Filling Machines.

A. On 5/14/24, <Redacted B4> Filling Machine <Redacted B4> faulted during the production of Vitamin D3 50,000 IU[/mL lot <Redacted B4> BUD 09 NOV 24 due to issues with the crimping station. Deviation# D-2024-017 was opened and the investigation is on-going.

B. On 5/15/24, during the filling operation for Lysine lot # < Redacted B4>, BUD: 31 AUG 24 on the <Redacted B4> Filling Machine <Redacted B4> ) the line was stopped numerous times for defective crimping. According to your firm you produced <Redacted B4> vials in total prior to stopping production. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

rilization process which incorporates the use of <Redacted B4> utilizing biological indicators within the lyophilizer.

2. On 5/14/24 in preparation for lyophilizing a diug product the next day per SOP #P-806, Operation

and Maintenance of the Lyophilizer, Section 8.6.5 your firm conducted a <Redacted B4> cleaning and sterilization of the interior chamber from 17:l0pm until 17:30pm with <Redacted B4> RTU and <Redacted B4> spraying the internal surfaces.

On 5/15/24 at 11:31am (approximately 19 hours later with no established hold time) during visual inspection of the interior chamber of your lyophilizer I observed residual liquid on multiple product shelves. Your firm was unable to provide evidence on what the residual liquid was and that it does not introduce contamination to your lyophilization cycle.

3. Your firm failed to include the stopper chute (product contact surface) within your cleanin ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring enviro nmental conditions.

Specifically, your firm failed to use a broth containing disinfectant neutralizers for your viable surface swab samples. Your firm conducts viable surface swab samples on the stopper bowl (product contact surface), filling needle (product contact surface) and tube transport port.

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Specifically, your firm does not assure that worst-case processing conditions for line speed are met as outlined in "Verification Protocol for Process 1 bv Aseptic Process Simulation". Per protocol, the 30mL size vial should be filled at the <Redacted B4> vials per minute (vpm) and the l0mL size vial should be filled at the <Redacted B4> vials per minute. Vials per minute is an output of all parameters set up on the <Redacted B4> filler. No vial per minute monitoring is performed during execution of aseptic processing simulations. In addition, on 5/14/2024, during observation of sterile filling for 30mL L-Lysine lot <Redacted B4>, the vials <Redacted B4> was observed to be <Redacted B4> <Redacted B4> which is slower than the worst-case scenario outlined in the aseptic process simulation protocol.

Observation 6

Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.

Specifically, your firm failed to investigate complaints received by your complaint intake team , including complaints related t o apparent adverse dru g events. Currently, your firm has identified 167 received complaints from 3/13/2024 -5/22/2024, and is working backwards by date to retrospectively capture all missed complaints.

In addition, these complaints were restored from a "Deleted Items" folder within the complaint intake

team's email folders. Additionally, your fnm did not document all complaints as required by complaint procedure "Complaint Handling, Drng Safety, and Surveillance". Complaints not investigated include but are not limited to:

a. Glutathione 200mg/mL lot <Redacted B4>, BUD 5/13/2024-this complainant stated that they had an adverse reaction and thought they were going into cardiac arrest.

b. B12 Methylcobalamin 5mg/mL lot <Redacted B4>,BUD 5/12/2024-this complainant stated a patient came into the clinic and received an injection of B12 and had to be rushed to the hospital.

c. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Your outsourcing facility has not submitted a report to FDA identifying a product compounded during the previous six months as required by section 503B(b )(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Specifically, drug products were compounded and not identified on your reports dated June 2023 and December 2023, including, but not limited to:

. PGEl (alprostadil) 40 mcg/mL injection . PGE3 (alprostadil) 150 mcg/mL injection . Sodium tetradecyl sulfate 0.1 % injection

. Sodium tetradecyl sulfate 0.3% injection . Zinc sulfate 10 mg/mL injection

***This is a repeated observation from the previous FDA Inspection dated 2/14-2/23/22.

Inspection Feb 14, 2022 to Mar 2, 2022: 13 observations

Firm on the cover
Olympia Compounding Pharmacy dba Olympia Pharmacy, 6700 Conroy Rd Ste 155, Orlando, FL 32835-3515
FEI number
3009724085
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Drug products failing to meet established specifications are not rejected.

Specifically, we identified approximately fifty-nine (59) lots that were out-of-specification (OOS) for potency/reconstitution time and were released by your firm from January 1, 2021 through February 16, 2022. The table below illustrates the eleven (11) lots currently on the market and within expiration date.

Drug Product

Lot#

Result

Specification I BUD

Disposition

BiMix (Papaverine 30mg/Phentolamine 3mg)

<Redacted B4> 88.8%

<Redacted B4>) 2/22/22 Expired

BiMix (Papaverine 30mg/Phentolamine 3mg)

88.8%

2/22/22 Expired

NAD + (Nicotinamide Adenine Dinucleotide) 500mcg <Redacted B4> Failed Reconstitution Time

Released and on the market

Sincalide 5mcg

110.4%

Released and on the market

market Sincalide 5mcg

(b) (41 Failed Reconstitution Time

(b) (4)

Released and on the market

NAD + (Nicotinamide Adenine Dinucleotide) 500mcg <Redacted B4> 85.6%

Released and on the market

F9 (Papaverine 0.9mg/lmL, Phentolamine 0.l mg/lmL, Alprostadil 20mcg/lmL, Ati·opine 0.0lmg/lm)

85%

4/19/22 Released and on the market

79.7%

4/26/22 Released and on the market

Semorelin Acetate 9mg/mL <Redacted B4> ...

Read the full 483 (PDF on fda.gov)

Observation 2

The quality control unit lacks responsibility to reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

Specifically, we identified approximately one hundred eighty-five (185) microbiological recoveries that were identified for personnel and environmental sampling conducted during production operations within the ISO 5 environment from July 2021 to February 2022. On 9/ 5/ 21, your firm-initiated deviation # D-2021-022 (closed on 12/ 15/ 21) due to post process <Redacted B4> sampling out-of-specification (OOS) results being found on sticky notes. The investigation stated from September 15, 2020, to September 15, 2021, all environmental monitoring showed no action limits within the critical filling zone, but this is not the case as evidenced by the following examples.

• <Redacted B4> Settle plate failure (1 cfu on 9/ 22/ 21) within Auto filler <Redacted B4> during production of Zinc Chloride lot# <Redacted B4>. ID: Staphylococcus warner.

TT6J14n • Post processing sampling failure (l cfu on 9/ 13/ 21) within Auto filler <Redacted B4> during production of NAO+ lot <Redacted B4>. ID: Paenibacil/us agaridevorans. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

• Your firm's SOP entitled, "Environmental Monitoring for the Positive and Negative Pressure Cleanrooms at Olympia Pharmacy", is inadequate as it fails to identify the critical sampling locations within your firm's ISO 5 LAFW during filling operations utilizing the <Redacted B4> and <Redacted B4>. For example, your firm did not provide scientific justification for omitting the product contact surface sample sites such as the filling needle or hopper which houses the stoppers within the <Redacted B4> filling machine which is in the ISO 5 LAFW.

• Your firm failed to have accountability of the environmental monitoring (EM) samples collected during/ after each batch production. On 2/ 14/ 22, your firm's QA Specialist was observed unloading the EM plates from the incubator. His process was to discard the sample if no growth was observed. When growth was observed he would set the sample aside to later count the colonies. No documentation occurred during this process. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency paiiiculate air filters under positive pressure.

Specifically, your July 13, 2021, Deviation #D-2021-007, which covered your April 2021 excursions identified below, was inadequate as it failed to evaluate whether your differential pressure specifications were suitable. In the investigation your firm indicated that your SOP # P-211 entitled, "Policy on Environmental and Personnel Monitoring Program" required a positively pressured specification of <Redacted B4> Data extracted from your electronic monitoring system reveals a <Redacted B4> specification from February 2021 to April 2021. In May to September 2021, the specification was changed to <Redacted B4> and then changed back to <Redacted B4> towards the end of September 2021 where it has remained. Furthermore, your Quality Director stated that there were no investigations into your June, August and November 2021 pressure excursions as identified within the table below.

Date

Alarm Triggered

Non-HD ISO 5 Cleanroom

Pressure during vial filling operations

Lot(s) affected

n/a

Cleanroom <Redacted B4> 0.002-0.038

<Redacted B4>

No ...

Read the full 483 (PDF on fda.gov)

Observation 5

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

1. Your firm failed to follow your SOP P-224 entitled, "Deviation Management", sections 7.5 Quality Evaluation (determining the impact of the deviation on safety, identity, strength, quality, and purity of the product) and section 7.6 Investigation (the investigation must include or eliminate other batches), etc., as evidenced by the following inadequate deviations conducted.

a. On 9/1/21 your firm-initiated Deviation #2021-020 due to Complaint #CC 2021-092 for NAD+ Lot # <Redacted B4>. The complainant stated the vials received were evaporated and contained a yeilow-like gel substance. Your firm's investigation determined the reason for the incomplete sublimation attributing the root cause as the technician failed to verify the stopper depth and the stopper was inserted too far into the vial. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

1. Your firm's SOP:P-304 entitled, "Cleaning of the Compounding Facility" reguires the following cleaning agents and respective contact times: <Redacted B4>, <Redacted B4> <Redacted B4> <Redacted B4>, (no contact time specified and <Redacted B4> used to clean the <Redacted B4> for <Redacted B4>, and <Redacted B4> cleaning but fail to require the documentation of the contact times as a form of verilication for the activity conducted. In addition, your firm was unable to provide the manufacturer's specified contact time for the <Redacted B4>. 1. *This is a repeated observation from the FDA-483 issued on 4/13/18

2. Your firm has not conducted any challenges for the cleaning validation/sterilization of the <Redacted B4> Auto filling machine therefore there is no documentation ensuring the residual detergents from your cleaning operations or residue from previous APis have been adequately removed.

3. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Results of stability testing are not used in determining expiration dates.

Specifically,

3. According to your Quality Manager, your firm lacks stability studies for your erectile dysfunction, vitamin, vein care, iv therapy and anti-aging sterile injectable drug products. Your firm did not conduct studies to demonstrate specifications including but not limited to potency, endotoxin, sterility, and container closure integrity remain suitable throughout each product's shelf life. Examples are identified in the table below:

endotoxin, sterility, and container closme integrity remain suitable throughout each product's shelf life. Examples are identified in the table below:

4. Your Glutathione 5ml stability study failed potency at its 3-month timepoint in December 2021.

You paused this stability study but continue to manufacture and distribute this product with a 3­

4-month BUD. Examples oflots released with a 4-month BUD ru.·\~~{4), (15) 4 )),[(15) (4l [(15) ( 4 ~. From 7 /1/21 to 2/14/22, your fom manufactured and distributed (b) ( 4 ~ vials of this diu g.

5. Your January 2021 Mitomycin 30ml stability study failed container-closure testing at its time 0 and 3-month timepoints. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Approved components, drug product containers and closures are not retested or reexamined as appropriate for identity, strength, quality and purity after exposure to conditions that might have an adverse effect with subsequent approval or rejection by the quality control unit.

Specifically, finished drug product, Sincalide 5mcg/Vial lot # <Redacted B4>, <Redacted B4> CPD 01 April 21, BUD 01 April 22 utilized expired (2/13/21) <Redacted B4>, <Redacted B4>, <Redacted B4> to manufacture the batch. Your firm also failed to locate the complete batch production record ( only the formulation sheet which identifies the Sincalide bulk lot # <Redacted B4> with no expiry date recorded for which your firm cannot locate the corresponding COA, labeling sheet and testing records were provided).

Observation 9

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, your firm lacks scientific data to support a hold time of approximately <Redacted B4> for Preserved Ascorbic Acid 500mg/mL, lot <Redacted B4> prior to <Redacted B4> to determine its bioburden.

Observation 10

The labels of your outsourcing facility's drug products are deficient.

4. The address and phone number of the outsourcing facility. Examples of product labels that do not contain this information: Chloramphenicol 50 mg/Sulfamethoxazole 50 mg/ Amphotericin B 5mg Capsules

5. The storage and handling instructions. Examples of product labels that do not contain this information: Chloramphenicol 50 mg/Sulfamethoxazole 50 mg/ Amphotericin B 5mg Capsules

6. A list of inactive ingredients, specifically the quantity or proportion of each ingredient. Examples of product labels that do not contain this information:

a. Lipode1m (Benzocaine 20%, Lidocaine 10%, Tetracaine 10%) Topical Cream

b. Lipode1m (Benzocaine 20%, Lidocaine 8%, Tetracaine 6%) Topical Cream

c. Lipode1m (Benzocaine 20%, Lidocaine 6%, Tetracaine 4%) Topical Cream

d. Lipode1m (Benzocaine 23%, Tetracaine 7%) Topical Cream

e. Lidocaine 23%/Prilocaine 10%/Phenylephrine 0.5% Topical Ointment

*This is a repeated observation from the FDA-483 issued on 4/13/18

Observation 11

The container labels of your outsourcing facility's drug products are deficient.

7. Information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1088; and

8. Route of administration

*This is a repeated observation from the FDA-483 issued on 4/13/18

Observation 12

Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.

Specifically, the following products were compounded and not identified on your report dated December 2021 .

9. Hydroquin 8%/fretin 0.05%/Hydrocoit 2.5% Cream

10. Azithromycin (ABX) 250mg

11. B12 Cyanocobalamin 2mg/ml

12. CantharadinPlus 10ml

13. Dexamethasone 0.33%

14. Glycolic Acid 50%

15. Hair Growth Fo1mulation: Minoxidil 5%/Fluocinolone 0.01 %/Tretinoin 0.01 %

16. Hydroquin 4%/Tretin 0.05%/Hydrocort 2% De1m Cream

17. Hydroquin 6%/Tretin 0.25%/ Kojic Ac 4%/ Hydrocort 0.05% Cream

18. Hydroquinone 6% Cream

19. Keto Topical: Keto 10%/Cyclobenz 2%/Baclof 2%/Lido 2/5%/Prilo 2.5% Topical Cream

20. Loomicaine (Prilocaine 14% /Lidocaine 14%)

~-~~~~---- 21. Lido 10%/Prilo 10%/Tetra 4 % Flavored <Redacted B4> I 22. Lido 23%/Tetra 7%/Prilo 2% <Redacted B4> 23. MONTH 1 NON INJ Weight Management Days 1-30, Naltrexone 1.5 mg, Se1morelin 500 mcg RDT, Lipo Trim Spray

24. MONTH 2 Weight Management Days 31-60, Naltrexone 3 mg, Se1morelin 9 mg, Lipo Trim Spray

25. MONTH 3+ Weight Management Days 61 +, Naltrexone 4.5 mg, Se1morelin 9 mg, Lipo Trim Spray

26. ...

Read the full 483 (PDF on fda.gov)

Observation 13

Your outsourcing facility compounds drug products using bulk drug substances that cannot be used in compounding under section 503B because they (a) have been identified in a federal register notice as not being placed on the 503B Bulk List and do not appear on the drug shortage list in effect under section 506E of the Act or (b) appear on the 503B Category 2 (bulk drug substances identified by FDA as presenting significant safety risk).

Specifically, your firm compounds drug products using bulk drug substances that are prohibited under section 503B, including, but not limited to folic acid.

Inspection Apr 6, 2018 to Apr 13, 2018: 10 observations

Firm on the cover
, OPS International Incorporated D/B/A Olympia Pharmacy 6700 Conroy Rd Ste 155, Orlando, FL 32835- 3515
FEI number
3009724085
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
4040 Nort h Cent ral Expressway, Suit e 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Protective apparel is not worn as necessary to protect drng products from contamination.

Specifically,

A. On 4/9/2018, your technician was observed in Buffer Room <Redacted B4> ISO 5 Classified) as having her neck exposed sporadically between the worn sterile hood and gown while aseptic manipulating a <Redacted B4> transfer of diug product, PGE-2, Lot # D3009.

B. On 4/9/2018, during EM sampling at sampling at <Redacted B4> Q], your phannacy technician was observed within your Non-Hazardous ISO 7, Prep Room <Redacted B4> without being adequately gowned while collecting EM samples. Your technician failed to follow your ffirm's gowning clean room procedure, Hand Hygiene and Garbing, P-404, Version 3, by not wearing a sterile gown.

Observation 2

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically,

A. Your procedure, Complaint Handling, P-219, Version 2, 28 July 16, fail to provide minimum

requirements for an adequate investigation to be conducted in order to detennine a root cause, customer complaint assessment requirements to assess for ADR reportability and the documentation of such actions.

B. Your quality unit failed to have conducted and documented an ADR assessment as pait of the following received customer complaints where your firm was made aware of potential side effects for your firm's compounded sterile diug products. 1. CC-2017-005, received 3/31/2017, RX for compounded sterile drug, 10 Testost CYP 200MG/ML *10 ML* Inj., Lot# A3218. 2. CC-2017-004, received 3/29/2017, RX #ODIGJl for compounded sterile diug, 20 Testost CYP 200MG/ML *10 ML* Inj, Lot# 11725. 3. CC-2017-001, received 2/17/2017, RX #ODD for compounded sterile drug, 600 Polidocanol 0.35% MDV (30 ML). 4. CC-2017-013, received 8/31/2017, RX for compounded drug, 60 Estriol .1 MG/CLOBET .5% PETROL, Lot# H0016.

1. #ODD

4. #ODD

C. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

D. Your procedure, Cleaning-Sterilizing and Disinfecting of the Compounding Facility, P-304,

Version 4 require the use of <Redacted B4> Ready to Use (Sterliant/Sporicidal) with a contact time of <Redacted B4> , and Ready to Use (Disinfectant) with a contact time of <Redacted B4> for <Redacted B4> and <Redacted B4> clean room cleaning but fail to require the documentation of contact times as a form of verification for activity. Your documented contact time for <Redacted B4> -Ready to Use (Sterliant/Sporicidal) of <Redacted B4> failed to meet the manufacturers requirement of <Redacted B4>.

contact times as a f01m of verification for activity. Your documented contact time forQDJQ] - Ready to Use (Sterliant/Sporicidal) ofBIJJ failed to meet the manufacturers requirement ofEa.

E. Your firm fails to have scientific data and or performed any studies in support <Redacted B4> Hand Sanitizer effectiveness as a disinfectant on sterile gloves used within your ISO 8, ISO 7, and ISO 5 classified clean room. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically, no lyophilized sterile drug product reconstitution specification has been established to be used as pair of the released criteria prior finished sterile drug product distribution. For example, your firm failed to establish a reconstitution specification for the release of the following drug products:

HCG

Sermorelin

Sermorelin GHRP

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, on 4/9/2018, your pharmacy technician was observed touching door between Ante Room <Redacted b4> (ISO 8 Classified) and Prep Room <Redacted B4> · ISO 7 Classified) during the entiy and exiting of the two rooms at the time of batch compounding mixing the drug product, PGE-2, Lot# D3009 without re-sanitizing sterile gloved hands with <Redacted B4> while transfening components in preparation for compound batch mixing.

Observation 6

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your procedure, Policy on the Environmental and Personnel Monitoring Program, P-211, Version 7 reports the <Redacted B4> recording of differential pressure shall be performed for all room. Your differential pressures are recorded <Redacted B4> and visually observe throughout the course of the day. On 4/9/2018, your firm was observed compounding the sterile drug product, PGE-2, Lot# D3009 which you began compounding at 2:20 pm and finished undergoing your <Redacted B4> process at 5:13 pm. Your recorded differential pressure for the non-hazardous clean room occurred at 7:00 am. No recorded differential pressure readings are available for the time in which the sterile drug 11g PGE-2 was mixed, compounded, and filled to show no excursions in differential pressure occurred.

h

Observation 7

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Specifically, during a review of your 2017 smoke study for your <Redacted B4> located in your non-hazardous sterile clean room, Buffer Room failed to adequately assess the most complicate filling configuration to ensure equipment appropriately designed and unidirectional air flow in the prevention of contamination that would alter the safety, identify, strength, quality, or purity of the sterile finished drug product. The firm's smoke study only assessed the filling for <Redacted B4> 10 mL clear vials in a tray.

Observation 8

Product Reporting:

Your outsourcing facility has not subinitted a report to FDA identifying a product compounded during the previous six months as required by section 503B(b )(2)(A). The following are examples of products that were compounded and not identified on your December 2017 product report::

F. alprostadil (PGE) 250 mcg/mL G. 300 mcg/mL and 350 mcg/mL injection H. anastrozole 0.5 mg and 0.75 mg capsule I. ascorbic acid 250 mg/mL and 500 mg/mL MDV J. avanafil 200 mg and 300 mg troche K. bacteriostatic water L. estradiol cypionate/testosterone cypionate 2 mg/50 mg/mL M. estradiol cypionate 2 mg/mL and 5 mg/mL injection

N. L-camitine 500 mg/mL MDV 0 . lysine 62.5 mg/arginine 50 mg cream P. papaverine 30 mg/mL injection MDV Q. phenylephrine 1 mg/mL injection R. sildenafil citrate 110 mg and 150 mg troch S. tadalafil 20 mg, 25 mg, 40 mg, and 75 mg troche T. terbutaline 3 mg capsule U. vardenafil 40 mg and 75 mg troche V. vitocin ( oxytocin) spray 40nJ/spray W. zinc chloride 10 mg/mL MDV.

This is not an all-inclusive list.

Observation 9

Product Labeling:

The labels of some of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A). Specifically,

X. The exact date the drug was compounded. Examples of product labels that do not contain this information include: NB-343 (papaverine 30 mg/ml; phentolamine 3 mg/ml; alprostadil 30 mcg/ml)

o Y. The expiration date. Examples of product labels that do not contain this

information include: NB-343 (papaverine 30 mg/ml; phentolamine 3 mg/ml; alprostadil 30 mcg/ml)

o z. Lot or batch number. Examples of product labels that do not contain this

information include: NB-343 (papaverine 30 mg/ml; phentolamine 3 mg/ml; alprostadil 30 mcg/ml)

0 AA. A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. Examples of product labels that do not contain this information include : NB-343 (papaverine 30 mg/ml; phentolamine 3 mg/ml; alprostadil 30 mcg/ml) QM4 (papaverine 30 mg/ml; phentolamine 3 mg/ml; alprostadil 300 mcg/ml; atropine 0.2 mg/ml)

Observation 10

The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(B).

Specifically,

BB. The phone number, 1-800-FDA-1088, to facilitate adverse event report ing. Examples of product labels that do not contain this information include: NB-343 (papaverine 30 mg/ml; phentolamine 3 mg/ml; alprostadil 30 mcg/ml) Polidocanol 2% injection Sodium bicarbonate 8.4°/o injection Testosterone cypionate 200 mg/ml injection HCG 10,000IU (lyophilized powder)

Linked 483s whose text is not shown

State board of pharmacy records

The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PH27363PharmacyOPS INTERNATIONAL INCORPORATED (dba OLYMPIA PHARMACEUTICALS)ORLANDOClear
PH27414PharmacyOPS INTERNATIONAL INCORPORATED (dba OLYMPIA PHARMACEUTICALS)ORLANDOClear
PH32627PharmacyOPS INTERNATIONAL INCORPORATED (dba OLYMPIA PHARMACY)ORLANDOClear
PH32707PharmacyOPS INTERNATIONAL INC. (dba OLYMPIA PHARMACY)ORLANDOClear
PH24080PharmacyLOWLITE INVESTMENTS (dba OLYMPIA PHARMACY)ORLANDOClosed
PH27446PharmacyLOWLITE INVESTMENTS, INC (dba Olympia Pharmacy)ORLANDOClosed

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Close but not exact board records

These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.

Nonresident licenses and board actions in other states

These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.

Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).

LicenseType as the board gives itName on the board recordLocationStatusPrior disciplinary orders (file flag)
33825Non Resident Sterile CompoundingOLYMPIA PHARMACYORLANDO, FLActiveNo

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 7422OSPOPS International IncOrlando, FLActive
OSP 5968OSPOPS International IncorporatedOrlando, FLExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054023245LICENSED PHARMACYOPS INTERNATIONAL INCORLANDO, FLACTIVE
054018748LICENSED PHARMACYOPS INTERNATIONAL INCORLANDO, FLCLOSED
054021641LICENSED PHARMACYOPS INTERNATIONAL INCORLANDO, FLCHANGE OF OWNERSHIP

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0003802NONRESIDENT PHARMACYOPS INTERNATIONAL INC. DBA OLYMPIA PHARMACY (dba OLYMPIA PHARMACY)ORLANDO, FLACTIVE (CURRENT)
PCN.0002712NONRESIDENT PHARMACYOPS INTERNATIONAL INC. (dba OLYMPIA PHARMACEUTICALS)ORLANDO, FLINACTIVE

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0013119Non Resident PharmacyOPS International IncorporatedORLANDO, FLActive
AD-0010094Outsourcing Facility-DistributorOPS INTERNATIONAL INCORPORATEDORLANDO, FLActive
A9-0001820Non Resident PharmacyOPS International Inc. (dba Olympia Pharmacy)ORLANDO, FLClosed
A9-0012540Non Resident PharmacyOPS International IncorporatedORLANDO, FLClosed
AA-0000024Outsourcing Facility-PharmacyOPS International Inc. (dba Olympia Pharmacy)ORLANDO, FLClosed

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301009877PharmacyOPS International IncorporatedOrlando, FLActive
5301012402PharmacyOPS INTERNATIONAL INCORPORATEDORLANDO, FLActive

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 1 product naming liraglutide under the labeler name “Olympia Pharmacy”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1). The compounded product reports cover FDA reporting periods 2026-1 to 2026-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
73198-151Liraglutide 6 mg/mLLiraglutide 6mg/mLINJECTION, SOLUTIONSUBCUTANEOUS6 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.